系统综述中的危害评估论文2:加巴喷丁系统综述中危害评估方法被忽视
该研究比较了加巴喷丁系统综述与荟萃分析(SRMA)中危害合成方法是否符合当前推荐。筛选4320条记录后纳入157篇SRMA,其中70篇为可靠综述;51/70(73%)报告遵循通用SRMA指南,但无一篇报告遵循危害合成专项推荐。作者结论认为现有危害评估方法流于形式,难以产生有效危害汇总以指导决策,需要范式转变。
要点
- 70篇可靠加巴喷丁SRMA中,51篇(73%)报告遵循通用SRMA指南,但无一篇报告遵循危害合成专项推荐。
- 所有评估领域中,综述方法主要针对获益问题设计,极少包含推荐的危害评估附加方法。
- 作者认为当前危害评估方法流于形式,难以产生有效危害汇总以指导决策,需要范式转变。
核心结论
- 所检查的SRMA中危害评估方法流于形式,不太可能产生有效的危害汇总以指导决策,需要范式转变。
- 作者建议至少应描述危害评估的局限性,并更清晰地描述危害合成方法。
研究设计与样本
- 遵循推荐系统综述实践,筛选可靠的加巴喷丁SRMA(符合预设方法学标准列表)且评估至少一种危害。
- 共筛选4320条记录,识别157篇加巴喷丁SRMA,其中70篇为可靠综述。
- 提取并比较四个领域的方法:预先指定、检索、分析和报告。
主要发现
- 70篇可靠综述中51篇(73%)报告遵循通用SRMA实施或报告指南,但无一篇报告遵循危害合成专项推荐。
- 在所有评估领域中,综述方法均针对获益问题设计,极少包含推荐的危害评估附加方法。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We compared methods used with current recommendations for synthesizing harms in systematic reviews and meta-analyses (SRMAs) of gabapentin. STUDY DESIGN & SETTING: We followed recommended systematic review practices. We selected reliable SRMAs of gabapentin (i.e., met a pre-defined list of methodological criteria) that assessed at least one harm. We extracted and compared methods in four areas: pre-specification, searching, analysis, and reporting. Whereas our focus in this paper is on the methods used, Part 2 examines the results for harms across reviews. RESULTS: We screened 4320 records and identified 157 SRMAs of gabapentin, 70 of which were reliable. Most reliable reviews (51/70; 73%) reported following a general guideline for SRMA conduct or reporting, but none reported following recommendations specifically for synthesizing harms. Across all domains assessed, review methods were designed to address questions of benefit and rarely included the additional methods that are recommended for evaluating harms. CONCLUSION: Approaches to assessing harms in SRMAs we examined are tokenistic and unlikely to produce valid summaries of harms to guide decisions. A paradigm shift is needed. At a minimal, reviewers should describe any limitations to their assessment of harms and provide clearer descriptions of methods for synthesizing harms.
引用
- Qureshi R, Mayo-Wilson E, Rittiphairoj T, et al. Harms in Systematic Reviews Paper 2: Methods used to assess harms are neglected in systematic reviews of gabapentin. J Clin Epidemiol. 2021. PMID: 34742789. doi:10.1016/j.jclinepi.2021.10.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。